News
Read the latest from M8.
Jul 24, 2024
M8 Pharmaceuticals, an Acino company, Signs Exclusive Agreement with LG Chem for Novel Treatments for Type 2 Diabetes and Osteoarthritis in Latin America
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/xs_logo_acino_news2.jpg 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/sm_logo_acino_news2.jpg 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/md_logo_acino_news2.jpg 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/lg_logo_acino_news2.jpg 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/xl_logo_acino_news2.jpg 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/xxl_logo_acino_news2.jpg 2400w)
May 07, 2024
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/228/xs_Supernus.jpg 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/228/sm_Supernus.jpg 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/228/md_Supernus.jpg 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/228/lg_Supernus.jpg 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/228/xl_Supernus.jpg 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/228/xxl_Supernus.jpg 2400w)
Apr 02, 2024
Acino announces new regional Leadership and hub to deliver on expanded presence and capabilities in LATAM following M8 acquisition Joel Barlan appointed as head of LATAM region
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/226/xs_ancino.jpg 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/226/sm_ancino.jpg 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/226/md_ancino.jpg 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/226/lg_ancino.jpg 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/226/xl_ancino.jpg 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/226/xxl_ancino.jpg 2400w)
Mar 19, 2024
SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/224/xs_acino-serb.png 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/224/sm_acino-serb.png 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/224/md_acino-serb.png 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/224/lg_acino-serb.png 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/224/xl_acino-serb.png 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/224/xxl_acino-serb.png 2400w)
Dec 04, 2023
Acino Completes Acquisition of M8 Pharmaceuticals Significantly Expanding Presence and Capabilities In Latin America
Sep 20, 2023
Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/220/xs_Picture1.png 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/220/sm_Picture1.png 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/220/md_Picture1.png 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/220/lg_Picture1.png 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/220/xl_Picture1.png 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/220/xxl_Picture1.png 2400w)
Aug 01, 2023
M8 Pharmaceuticals obtains market authorization for Barlo® (Carragelose®) nasal spray in Mexico
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/218/xs_md_marinomed.jpg 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/218/sm_md_marinomed.jpg 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/218/md_md_marinomed.jpg 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/218/lg_md_marinomed.jpg 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/218/xl_md_marinomed.jpg 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/218/xxl_md_marinomed.jpg 2400w)
Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/216/xs_xdw.jpg 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/216/sm_xdw.jpg 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/216/md_xdw.jpg 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/216/lg_xdw.jpg 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/216/xl_xdw.jpg 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/216/xxl_xdw.jpg 2400w)
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
M8 Pharmaceuticals, an Acino company, Signs Exclusive Agreement with LG Chem for Novel Treatments for Type 2 Diabetes and Osteoarthritis in Latin America
Jul 24, 2024
![](https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/xs_logo_acino_news2.jpg 320w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/sm_logo_acino_news2.jpg 640w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/md_logo_acino_news2.jpg 1024w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/lg_logo_acino_news2.jpg 1400w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/xl_logo_acino_news2.jpg 1800w,https://cms.m8pharmaceuticals.com/system/uploads/fae/image/asset/230/xxl_logo_acino_news2.jpg 2400w)
MEXICO CITY, July 24, 2024 /PRNewswire/ -- M8 Pharmaceuticals, an Acino company ("M8"), today announces the signature of an exclusive licensing and distribution agreement with LG Chem Ltd., a global company headquartered in South Korea that specializes in life sciences as one of its core businesses, to market, commercialize, and distribute Hyruan One® in Brazil, and Zemiglo® and Zemimet® SR (Zemiduo® SR in Mexico) in Mexico, Central America, and the Dominican Republic.
Gemigliptin, sold under the brand names Zemiglo® and Zemimet® SR (Zemiduo® SR in Mexico), is a reversible, potent, selective, competitive, and long-acting inhibitor of dipeptidyl peptidase (DPP)-4, for use as monotherapy or in combination with metformin or sulfonylureas (SU) to treat hyperglycemia in patients with Type 2 diabetes. The once-daily Zemimet® SR (Zemiduo® SR in Mexico) is currently the number one brand in the Type 2 diabetes market in South Korea.
Hyruan One® is a single-injection treatment of hyaluronic acid (HA), also known as sodium hyaluronate, to replace diseased synovial fluid and restore the loss of viscoelasticity in joints caused by osteoarthritis (OA). Formulated with cutting-edge technology, Hyruan One® is a biofermented, cross-linked HA injection indicated for the treatment of OA of the knee.
This strategic partnership aligns with Acino's mission to provide the people of Latin America with improved access to innovative medicines, strengthening M8's presence as a key provider of treatments for cardiometabolic diseases in the region, and paving the way for greater patient access to novel treatments for Type 2 diabetes. It also enables M8 to expand into an additional therapeutic area in Brazil, offering a new one-shot option, with high molecular weight, for patients living with OA.
"We are delighted to enter this partnership with LG Chem. The addition of Zemiglo® and Zemimet® SR to M8's portfolio marks an important milestone in our innovation journey," said Joel Barlan, Head of Latin America at Acino. "We continue to pursue our purpose of increasing patient access to quality healthcare, collaborating with leading pharmaceutical companies like LG Chem to develop a pipeline of specialty treatments for the benefit of our patients."
"We look forward to working alongside M8 Pharmaceuticals. Their proven track record and superior marketing and sales capabilities makes them ideally placed to ensure that LG Chem's diabetes and OA products improve the lives of many patients in Mexico, Brazil, and other regions in Latin America," said Inchul Hwang, Vice President and Head of Primary Care Business Unit of LG Chem.
ENDS
**About M8 Pharmaceuticals, an Acino company
M8 is a specialty biopharmaceutical company focused on licensing, marketing, and distributing innovative and established therapeutics in Latin America. We aim to become the preferred pharmaceutical partner for licensing high-value, innovative, and proven therapies across our main therapeutic areas: CNS, respiratory, cardiometabolic, immunology, gastroenterology, onco-hematology, and rare diseases. Our mission is to provide the people of Latin America with access to the innovative and proven medicines they need to transform their lives. In December 2023, M8 was acquired by Acino, a Swiss pharmaceutical company headquartered in Zurich.
**About Acino
Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. We deliver quality pharmaceuticals to promote affordable healthcare in these markets. We leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information, please visit www.acino.swiss .
Acino is part of Arcera, a global company in the life sciences sector headquartered in Abu Dhabi, United Arab Emirates. Arcera was established by ADQ, an Abu Dhabi-based investment and holding company, to build a global life sciences powerhouse poised to make significant contributions to realising the UAE's aspiration to emerge as a frontrunner in science and technology. To learn more about Arcera, please visit www.arceralifesciences.com .
**About LG Chem
LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem Life Sciences develops, manufactures, and globally commercializes pharmaceutical products with a focus on Oncology, Immunology, and Metabolic diseases. Our mission is to transform people's lives through inspiring science and leading innovation. For more information, please visit www.lgchem.com.
For more details, please contact:
Larisa Bernstein, Global Head of Communications, Acino larisa.bernstein@acino.swiss
Son Junil / Kim Junam, Professionals, Communications Team, LG Chem lgchempr@webershandwick.com
SOURCE M8 Pharmaceuticals